01584nas a2200265   4500000000100000008004100001653003900042653001800081653001400099653002200113653001100135100001400146700001100160700001200171700001600183700001200199700001100211700001200222700001200234700001800246245017300264856009000437520077700527022001401304       2016                            d10aNeglected tropical diseases (NTDs)10aLeishmaniasis10aTreatment10aCapacity building10aAfrica1 aWasunna M1 aMusa A1 aHailu A1 aKhalil EA G1 aOlobo J1 aJuma R1 aWells S1 aAlvar J1 aBalasegaram M00aThe Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis.  uhttp://trstmh.oxfordjournals.org/content/early/2016/06/07/trstmh.trw031.full.pdf+html3 a<p>Visceral leishmaniasis is a neglected tropical disease endemic in East Africa where improved patient-adapted treatments are needed. The Leishmaniasis East Africa Platform (LEAP) was created in 2003 to strengthen clinical research capacity, serve as a base for training, and evaluate and facilitate implementation of new treatments. Major infrastructure upgrades and personnel training have been carried out. A short course of Sodium Stibogluconate and Paramomycin (SSG&amp;PM) was evaluated and is now first-line treatment in the region; alternative treatments have also been assessed. LEAP can serve as a successful model of collaboration between different partners and countries when conducting clinical research in endemic countries to international standards.</p>
  a1878-3503